Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1510201049
Ticker CELG
Company CELGENE
Currency $
Price
Aware Investor Index (AII) 0.0574
Recommendation SELL
P/E 122.30
ROE 13.93 %
Capitalization 100,835,776,000 $
Dividend Yield 0.00 %
P/S 10.89
AII Position 531
P/E Position 733
ROE Position 278
Capitalization Position 82
Dividend Yield Position 629
Sales 9,256,000,000 $
10-Year Average Earnings 824,515,000 $
Shares Outstanding 824,900,000
Equity 5,919,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com







Sales:

YEAR MONTH AMOUNT
2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $

Earnings:

YEAR MONTH AMOUNT
2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $
2008 12 -1,533,653,000.00 $
2007 12 226,433,000.00 $
2006 12 68,981,000.00 $

Equity:

YEAR MONTH AMOUNT
2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284

 












Bloomberg News for CELGENE:

Oct 26, 2017
Is Celgene's Fortune Running Out? Wall Street Looks for Answers
thing in the press release is that CELG has now taken down its 2020 guidance. The net decrease of $1 billion in 2020 numbers is due to lower expectations for CELG’s Oncology and I&I franchises offset...
Jul 26, 2017
U.S. Equities Steady as Investors Await Fed; Tech Shares Higher
Helmerich & Payne Inc (HP), PG&E Corp (PCG), Comcast Corp (CMCSA), BorgWarner Inc (BWA),Celgene Corp (CELG), Johnson Controls International plc (JCI), Xcel Energy Inc (XEL),L3 Technologies Inc (LLL), Boston...
Aug 4, 2010
Arbitrage Profit in U.S. Takeovers Pending on Aug. 4
08/25/10 ARG US APD US 63.50 65.30 -1.80 -2.76 77,416 Cash 08/13/10 ABII US CELG US 72.75 75.78 -3.03 -3.99 2,776 C&S 12/31/10 CASY US ATD/B CN 36.75 ...
Feb 10, 2012
Nasdaq Short Interest as of Jan. 31
642 5,536 CECE CECO ENVIRONMNTL 6,147 7,504 31,975 CELG CELGENE CORP 7,920,994 9,159,230 3,595,048 CELGZ CELGENE CORP-CVR...
Jan 21, 2011
S&P 500 Stocks With Biggest Gap Between Market Price, Estimate
15.30 19.39 -8.43 BAC BANK OF AMERICA 26.4 23 14.34 18.13 -11.57 CELG CELGENE CORP 26.2 22 56.37 71.14 -2.40 GME GAMESTOP CORP-A 25...
Jan 7, 2011
S&P 500 Stocks With Biggest Gap Between Market Price, Estimate
46.18 55.88 -2.48 JPM JPMORGAN CHASE 20.8 22 43.28 52.30 1.77 CELG CELGENE CORP 20.8 22 59.34 71.68 4.61 CSCO CISCO SYSTEMS 20...
Jun 17, 2010
50 Top Performers
from Apple (AAPL) (No. 4) and Google (GOOG) (No. 16) to biotechnology players such as Celgene (CELG) (No. 13) and Gilead Sciences (GILD) (No. 26), a leader in drugs to fight HIV. The big surprise...
Jan 13, 2010
North and South American Stock Rating Changes, New Coverage
-------------------------------------------------------------------------------- Celgene Corp (CELG US) EVA Dimensions Analyst Recommendation Action Target Team Coverage ...
Nov 13, 2003
Dreyer's Grand and Salem Lead `Sky High Six': John Dorfman
20, 2002, through Tuesday, Nov. 11. Celgene and Dreyer'sThe biggest gainer was Celgene Corp. (CELG), up 57 percent. Also strong was Herman Miller Inc. (MLHR), up 30 percent, and AVX Corp. (AVX)...
Sep 16, 2003
Biotech Regains Its Strength
among the biotech issues he covers? He has 5-STARS (buy) rankings on Amgen (AMGN ), Celgene (CELG ), Genzyme (GENZ ), MedImmune (MEDI ), and Millennium Pharmaceuticals (MLNM...


Google News for CELGENE:

StreetInsider.com - 5 days ago
Deutsche Bank Starts Celgene (CELG) at Hold
Deutsche Bank initiates coverage on Celgene (NASDAQ: CELG) with a Hold rating and a price target of $114.00. Analyst Navin Jacob commented, "Following the discontinuation of GED-301 on 10/19/17 and 2020 guidance cut on 10/26/17, CELG stock declined 25% (peer group: -13% same time period).
The Ledger Gazette - 15 hours ago
Head-To-Head Contrast: Celgene (CELG) vs. Valeant ...
Celgene (NASDAQ: CELG) and Valeant Pharmaceuticals International (NYSE:VRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and ...
Nasdaq - 28 Nov 2017
Why Is Celgene (CELG) Up 3.4% Since the Last Earnings Report?
Celgene reported mixed results in third-quarter 2017 wherein earnings beat expectations but sales failed to meet estimates. The company reported adjusted earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.88, up from $1.58 in the year-ago quarter. Total revenues grew 10.2% to ...
Nasdaq - 30 Nov 2017
Oversold Conditions For Celgene (CELG)
In trading on Thursday, shares of Celgene Corp. (Symbol: CELG) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $100.35 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 75.7. A bullish investor could look at CELG's 29.9 RSI ...
Dispatch Tribunal - 8 hours ago
Celgene (CELG) Downgraded to Buy at Vetr
Celgene logo Celgene (NASDAQ:CELG) was downgraded by equities researchers at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday. They currently have a $121.72 price objective on the biopharmaceutical company's stock. Vetr's price target would suggest ...
Economic News
Celgene (CELG) & bluebird bio (BLUE) Report Updated Results ...
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (NASDAQ: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory ...
The Ledger Gazette
2 Stocks to keep an eye on Today: Celgene Corporation (CELG ...
Celgene Corporation (NASDAQ:CELG) market capitalization at present is $85.22B at the rate of $109.41 a share. The firm's price-to-sales ratio was noted 6.89 in contrast with an overall industry average of 3.92. Most of the active traders and investors are keen to find ways to compare the value of stocks.
TopChronicle
Celgene (CELG) Presents at Evercore ISI Biopharma Catalyst/Deep ...
Celgene (CELG) Presents at Evercore ISI Biopharma Catalyst/Deep Dive Conference (Transcript). Nov.30.17 | About: Celgene Corporation (CELG). Celgene Corp. ... We have Scott Smith and Patrick Flanigan from Celgene joining us. And I'm extremely excited because they told me they'll discuss 2025 data with us today.
StreetInsider.com - 11 Dec 2017
Fewer Negatives Lift Ranking of Celgene (CELG) to Hold
With a $83.5 billion market value, Celgene Corp (NASDAQ:CELG) ranks in the top 10% of its industry group, Biotechnology, and in the top decile of sector group, Health Care, in market value. From the prospective of investment attractiveness, The current Portfolio Grader ranking for CELG puts it 183 among ...
Endpoints News
Celgene: Revlimid's Price Hikes Could Attract Senate's Attention
Celgene (CELG) missed on Q3 revenue and gave weak forward guidance. Other than weak guidance the quarterly results looked fine. Top line growth was 11% ... This is important as it gives investors comforts that Celgene is still a growth company. However, the company had to hike prices in order to do it.


Back